Geneva, Switzerland (PRWEB) June 28, 2011
Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today the Company’s CEO, Igor Fisch, Ph.D., will present “From Clinical Candidate to Product Manufacturing: Shrinking Protein Drug Development Timeline with Designer Cell Lines” at the GEN Drug Discovery Theater on June 29, 2011 at 10:00 AM. The GEN Theater presentations are part of the BIO International Convention being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.
From discovery to manufacturing, successful biologics development requires robust expression systems. For most protein therapeutics, the manufacturing system of choice is Chinese hamster ovary (CHO) cells. For the past 10 years, Selexis has developed patented technology, proprietary CHO-M cell lines and scale-up processes to produce CHO manufacturing cell lines for clients that routinely achieve expression levels of 2-5 g/L. However, even with these technologies, certain classes of proteins, such as fusion proteins, can be difficult to express. Selexis will present data on their new designer CHO cell lines that are being developed to overcome the protein expression bottlenecks associated with these hard-to-express proteins.
Selexis will also be exhibiting in booth number #1906 located in Hall A – Discovery Zone (http://e.mybio.zerista.com/exhibitor/member/17326) . For the exhibit hall schedule, visit: http://e.mybio.zerista.com/event/print
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.
For more information visit http://www.selexis.com